Cellectis
CLLS
27 hedge funds and large institutions have $18.3M invested in Cellectis in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 7 closing their positions.
0.18% less ownership
Funds ownership: 13.73% → 13.56% (-0.18%)
13% less funds holding
Funds holding: 31 → 27 (-4)
30% less capital invested
Capital invested by funds: $26.1M → $18.3M (-$7.84M)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
76% less call options, than puts
Call options by funds: $8K | Put options by funds: $33K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$3.77M |
| 2 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$341K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$70K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$40.2K |
| 5 |
Baird Financial Group
Milwaukee,
Wisconsin
|
+$39.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OC
Oppenheimer & Co
New York
|
-$355K |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$314K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$72.5K |
| 4 |
Two Sigma Investments
New York
|
-$25.2K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$4K |
CLLS Hedge Fund Activity: Q2 2024 in Review
27 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q2 2024, worth a combined $18.3M — down 30% from $26.1M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CLLS and 4 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was UBS AM, opening a new position worth an estimated $3.77M. The largest seller was Oppenheimer & Co, exiting entirely with an estimated $355K sold.
- 27 institutional investors held Cellectis (CLLS) as of Q2 2024, down from 31 in Q1 2024.
- Funds reported $18.3M of Cellectis stock for Q2 2024, down 30% quarter-over-quarter.
- 4 funds opened new Cellectis positions in Q2 2024 and 7 closed out, a net change of -3 holders.
- The largest Cellectis buyer in Q2 2024 was UBS AM, an estimated $3.77M added.
- The largest Cellectis seller in Q2 2024 was Oppenheimer & Co, an estimated $355K sold.
Based on aggregated 13F filings for Q2 2024.